Chengda Biotech eyes listing in Hong Kong

vaccination 230 x 150
By John Loh
31 Oct 2018

Liaoning Chengda Biotechnology filed for a Hong Kong flotation on Tuesday through sponsors CLSA and GF Capital.

The division of Shanghai-listed Liaoning Cheng Da was one of the largest China-based manufacturers of vaccines in 2017 by net profit and revenue, according to Frost & Sullivan research cited in the prospectus.

What makes the IPO-hopeful stand out is the fact that, unlike the initial crop of ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial